Table 2.
Univariate analysis of the infections in the MM patients
| Factors | Investigated cases (n = 161) |
Group with infections (%) (n = 126) |
Group without infections (%) (n = 35) |
χ2 | P value |
|---|---|---|---|---|---|
| Sex | 3.132 | 0.077 | |||
| Male | 94 | 69 (73.4) | 25 (26.6) | ||
| Female | 67 | 57 (85.1) | 10 (14.9) | ||
| Age | 2.583 | 0.108 | |||
| <60 | 51 | 36 (70.6) | 15 (29.4) | ||
| ≥ 60 | 110 | 90 (81.8) | 20 (18.2) | ||
| ECOG score | 4.294 | 0.038 | |||
| ≤ 2 | 100 | 73 (73.0) | 27 (27.0) | ||
| >2 | 61 | 53 (86.9) | 8 (13.1) | ||
| Immunophenotype | 0.672 | 0.880 | |||
| IgG | 70 | 54 (77.1) | 16 (22.9) | ||
| IgA | 49 | 39 (79.6) | 10 (20.4) | ||
| Light chain | 32 | 26 (81.3) | 6 (18.8) | ||
| Others | 10 | 7 (70.0) | 3 (30.0) | ||
| Durie-Salmon stage | 6.540 | 0.011 | |||
| Stage I-II | 36 | 23 (63.9) | 13 (36.1) | ||
| Stage III | 122 | 102 (83.6) | 20 (16.4) | ||
| ISS stage | 7.728 | 0.005 | |||
| Stage I-II | 56 | 37 (66.1) | 19 (33.9) | ||
| Stage III | 101 | 86 (85.1) | 15 (14.9) | ||
| RBC (/L) | 0.448 | 0.503 | |||
| < 3.8 × 1012(f); | 153 | 121 (79.1) | 32 (20.9) | ||
|
< 4.3 × 1012(m) ≥3.8 × 1012(f); ≥4.3 × 1012(m) |
8 | 5 (62.5) | 3 (37.5) | ||
| Haemoglobin (g/L) | 6.092 | 0.014 | |||
| <90 | 98 | 83 (84.7) | 15 (15.3) | ||
| ≥ 90 | 63 | 43 (68.3) | 20 (31.7) | ||
| ANC (/L) | 0.000 | 1.000 | |||
| <1.5 × 109 | 19 | 15 (78.9) | 4 (21.1) | ||
| ≥ 1.5 × 109 | 142 | 111 (78.2) | 31 (21.8) | ||
| ALC (/L) | 3.676 | 0.055 | |||
| < 1.0 × 109 | 38 | 34 (89.5) | 4 (10.5) | ||
| ≥ 1.0 × 109 | 123 | 92 (74.8) | 31 (25.2) | ||
| CRP (mg/L) | 7.235 | 0.007 | |||
| ≤ 10 | 95 | 69 (72.6) | 26 (27.4) | ||
| >10 | 62 | 56 (90.3) | 6 (9.7) | ||
| Albumin (g/L) | 3.155 | 0.076 | |||
| <35 | 111 | 91 (82.0) | 20 (18.0) | ||
| ≥ 35 | 49 | 34 (69.3) | 15 (30.6) | ||
| Globulin (g/L) | 0.056 | 0.813 | |||
| ≤ 30 | 39 | 31 (79.5) | 8 (20.5) | ||
| >30 | 121 | 94 (77.7) | 27 (22.3) | ||
| Serum creatinine (μmol/L) | 0.450 | 0.502 | |||
| <177 | 117 | 90 (76.9) | 27 (23.1) | ||
| ≥ 177 | 44 | 36 (81.8) | 8 (18.2) | ||
| Serum calcium (mmol/L) | 0.651 | 0.420 | |||
| ≤ 2.75 | 149 | 115 (77.2) | 34 (22.8) | ||
| >2.75 | 12 | 11 (91.7) | 1 (8.3) | ||
| β2-MG (mg/L) | 1.805 | 0.179 | |||
| <5.5 | 69 | 51 (73.9) | 18 (26.1) | ||
| ≥ 5.5 | 87 | 72 (82.8) | 15 (17.2) | ||
| LDH (U/L) | 0.124 | 0.725 | |||
| ≤ 243 | 105 | 85 (81.0) | 20 (19.0) | ||
| >243 | 32 | 25 (78.1) | 7 (21.9) | ||
| Bone destruction | 3.581 | 0.058 | |||
| Yes | 99 | 82 (82.8) | 17 (17.2) | ||
| No | 60 | 42 (70.0) | 18 (30.0) | ||
| Invasive operation | 1.193 | 0.275 | |||
| Yes | 138 | 110 (79.7) | 28 (20.3) | ||
| No | 23 | 16 (69.6) | 7 (30.4) | ||
| Renal dysfunction | 1.213 | 0.271 | |||
| Yes | 52 | 38 (30.2) | 14 (40.0) | ||
| No | 109 | 88 (69.8) | 21 (60.0) | ||
| Cardiac dysfunction | 0.373 | 0.541 | |||
| Yes | 31 | 23 (18.3) | 8 (22.9) | ||
| No | 130 | 103 (81.7) | 27 (77.1) | ||
| Hypertension | 0.814 | 0.367 | |||
| Yes | 63 | 47 (37.3) | 16 (45.7) | ||
| No | 98 | 79 (62.7) | 19 (54.3) | ||
| Diabetes | 0.915 | 0.229 | |||
| Yes | 24 | 17 (13.5) | 7 (20.0) | ||
| No | 137 | 109 (86.5) | 28 (80.0) |
ECOG Eastern Cooperative Oncology Group, ISS International Staging System, RBC Red Blood Cells, f female, m male, ANC Absolute Neutrophil Count, ALC Absolute Lymphocyte Count, CRP C-reactive protein, β2-MG β2-microglobulin, LDH lactate dehydrogenase
Reference ranges of the laboratory values in our study: RBC 3.8 ~ 5.1 × 1012 (f), 4.3 ~ 5.8 × 1012/L(m); CRP ≤ 10 mg/L.